The All Ordinaries Index (ASX: XAO) is down 0.3% in late morning trade on Thursday, but don't blame this rocketing ASX All Ords healthcare share.
The high-flying stock in question is Aroa Biosurgery Ltd (ASX: ARX).
Shares in the soft-tissue regeneration company closed yesterday trading for 55 cents. At time of writing, shares are changing hands for 65 cents apiece, up 18.2%.
Here's what's piquing investor interest today.
Image source: Getty Images
ASX All Ords healthcare share rockets on guidance beat
Investors are bidding up Aroa shares today following the release of the company's preliminary full year results (FY 2026). Aroa's financial year runs through to 31 March.
The ASX All Ords healthcare share reported full year revenue of NZ$104 million in actual terms. On a constant currency basis, FY 2026 revenue came in at NZ$101 million.
That sees revenue coming in above Aroa's full year guidance range of NZ$92 million to NZ$100 million (constant currency). It's also 21% higher than FY 2025 total revenue.
Management credited the strong growth to a 52% year-on-year boost (constant currency) in sales in its Myriad portfolio, which was stronger than they had expected. Myriad is the company's propietary biological surgical implant used to regenerate soft tissue.
On the earnings front, the ASX All Ords healthcare share expects FY 2026 normalised earnings before interest, taxes, depreciation and amortisation (EBITDA) to be in the range of NZ$11million to NZ$12 million on an actual basis. Or NZ$10 million to NZ$11 million on a constant currency basis.
That also materially exceeds Aroa's FY 2026 constant currency earnings guidance of NZ$5 million to NZ$8 million.
The earnings boost was primarily driven by the increased revenue. The company noted that changes in the timing of project related costs, particularly its Enivo and TelaBio development projects, also had some impact. Aroa now expects these costs to be realised in FY 2027.
In other core financial metrics, Aroa has a positive net cash flow of NZ$5 million over the full year.
And on the balance sheet, the company held NZ$27 million at 31 March, up from NZ$23 million at 30 September.
What did Aroa management say?
Commenting on the preliminary results sending the ASX All Ords healthcare share surging today, Aroa CEO Brian Ward said:
We are delighted with the strong performance reflected in these preliminary results, driven by continued growth in the Myriad portfolio. We look forward to providing further details on the release of our audited full year results at the end of May.
Aroa is scheduled to release its fully audited FY 2026 results on 26 May.
